A recent publishing of the first part of the CPHI Annual Report predicts substantial progress ahead for artificial intelligence (AI)’s use in pharma, despite the uproar surrounding ChatGPT and other AI programs. According to a press release, the implications go to the extent that within the next 10 years, more than 50% of approved drugs will involve AI in their development and/or manufacturing.
The findings come ahead of CPHI Barcelona held at Fira Barcelona from Oct. 24–26, 2023. The report features insights from 250 global pharma companies and is seen as a key indicator of the industry’s future growth prospects, according to the press release. This year is the first time in the report’s history that pharmaceutical “AI companies” (26%) have overtaken “late stage” (20%) and “early stage” (19%) biotechs as the industry’s most appealing investment option.
